Esperion Therapeutics
ESPR
ESPR
163 hedge funds and large institutions have $1.11B invested in Esperion Therapeutics in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 58 increasing their positions, 41 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
163
Holders Change
+7
Holders Change %
+4.49%
% of All Funds
3.53%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.13%
New
29
Increased
58
Reduced
41
Closed
22
Calls
$14M
Puts
$26.5M
Net Calls
-$12.5M
Net Calls Change
+$37.9M
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
$8.72M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
$46.1M |
| 3 |
Renaissance Technologies
New York
|
$7.85M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$18.7M |
| 5 |
Millennium Management
New York
|
$9.96M |
Top Sellers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
$65.3M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
$39.1M |
| 3 |
Citigroup
New York
|
$647K |
| 4 |
UBS Group
Zurich,
Switzerland
|
$997K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
$23.3M |
